Axbio
Private Company
Total funding raised: $20M
Overview
Axbio is a privately-held biotechnology company pioneering a foundational Bio-CMOS platform that merges semiconductor manufacturing with biology to create next-generation tools for sequencing and multiplex molecular diagnostics. Its core technology centers on a proprietary, high-density nanopore sequencing chip and an electrochemical microarray detection system, aimed at delivering ultra-high throughput and low-cost instruments and consumables. With a seasoned leadership team from Silicon Valley and strong backing from global venture capital, the company is advancing its first commercial product, the AxiLona EL-100 microarray analyzer, through regulatory approval in China while developing its flagship AxiLona AXP-100 nanopore sequencer. Axbio operates at the intersection of multiple high-growth markets, including genomics, precision diagnostics, and synthetic biology.
Technology Platform
Microfluidic Bio-CMOS platform integrating high-density nanopore sequencing chips, electrochemical sensors, microfluidics, synthetic biology, and AI for multi-omics research and molecular diagnostics.
Funding History
1Opportunities
Risk Factors
Competitive Landscape
Axbio competes in the DNA sequencing arena against dominant players like Illumina (short-read), Pacific Biosciences (long-read), and Oxford Nanopore Technologies (long-read), and in multiplex diagnostics against companies like Luminex and Qiagen. Its unique proposition is the deep integration of CMOS chip manufacturing to achieve density and cost advantages, but it must overcome significant barriers of ecosystem maturity, brand recognition, and clinical validation established by these competitors.